Vaxent chief scientific officer James B. Dale, who also serves as a professor of medicine and chief of the division of infectious diseases at the University of Tennessee Health Science Center, invented StreptAnova based on more than 25 years of laboratory research.
The vaccine was developed by Dr. James Dale at the University of Tennessee Health Science Center and is being commercialized by PREVENT and Vaxent. The Phase I trial was announced in August.
Dr. James B. Dale developed StreptAnova at the University of Tennessee Health Sciences Center. . . StreptAnova will soon undergo a Phase 1 clinical trial in Halifax, Nova Scotia, to test its effectiveness and whether it is safe for humans.
StreptAnova® was invented by James B. Dale, M.D., Chief of the Division of Infectious Diseases, and Gene H. Stollerman, M.D., Endowed Professor in Medicine at the University of Tennessee Health Science Center (UTHSC), and Research Scientist at the Memphis Veterans Affairs Medical Center. It is being commercialized jointly by PREVENT and Vaxent, a company founded… Read More
StreptAnova® was invented by Dr. James B. Dale at the University of Tennessee Health Science Center (UTHSC), and is being commercialized jointly by PREVENT and Vaxent, a company founded by Dr. Dale.
StreptAnova® was invented by Dr. James B. Dale at the University of Tennessee Health Science Center (UTHSC), and is being commercialized jointly by PREVENT and Vaxent, a company founded by Dr. Dale.
